ReviewImmunoTargets and therapy2020
Therapeutic Vaccines for HPV-Associated Malignancies.
Review in ImmunoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Determinants of human papillomavirus vaccination uptake in Nigeria: a mixed-methods systematic review.BMC public health · 2026Pooled it
- Pooled it
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.Journal for immunotherapy of cancer · 2023Guideline
- Pooled it
- Clinical research progress and challenges of vaccine for human papillomavirus-associated cancers.Human vaccines & immunotherapeutics · 2026Review
- Colorectal cancer and tumor vaccines (Review).Oncology letters · 2026Review
- Article
- An Outer Membrane Vesicle-Based Vaccine Combined with alb-Flt3L Promotes Durable Antitumor Immunity in HPV-Associated Cancer.Vaccines · 2026Article
- Exploring the Chemical Space Around Protoflavonoids: Synthesis and Antitumor Activity of Protochalcones.ChemMedChem · 2026Article
- Human Papillomavirus: Update in Bridging Basic Science to Clinical and Public Health Innovations.Health science reports · 2026Article
- Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity.Journal of experimental & clinical cancer research : CR · 2026Article
- Molecular Insights into HPV-Driven Head and Neck Cancers: From Viral Oncoproteins to Precision Therapeutics.Viruses · 2025Review
- Emerging Therapeutic Strategies for HPV-Related Cancers: From Gene Editing to Precision Oncology.Current issues in molecular biology · 2025Review
- New mouse model based on adenocarcinoma 4T1 cells expressing HPV16 E6 and E7 applied to assess the efficacy of therapeutic and prophylactic E6/E7-based HPV16 vaccines.Infectious agents and cancer · 2025Article
- The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances.Biomolecules & biomedicine · 2025Review
- Molecular mechanisms of viral oncogenesis in haematological malignancies: perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling.Experimental hematology & oncology · 2025Review
- Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy.Journal for immunotherapy of cancer · 2025Article
- Nanovaccines against Cervical Cancer: Reliable Strategies to Circumvent Limitations of Traditional Therapeutic Vaccines.Advanced pharmaceutical bulletin · 2025Review
- Unraveling HPV-associated cancer complexity: From molecular insights to innovative therapies.Heliyon · 2025Review
- Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates.Immunotherapy · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV)-related malignancies are responsible for almost all cases of cervical cancer in women, and over 50% of all cases of head and neck carcinoma. Worldwide, HPV-positive malignancies account for 4.5% of the global cancer burden, or over 600,000 cases per year. HPV infection is a pressing public health issue, as more than 80% of all individuals have been exposed to HPV by age 50, representing an important target for vaccine development to reduce the incidence of cancer and the economic cost of HPV-related health issues. The approval of Gardasil
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.